2 results
Not approvedWill not start
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
Approved WMOPending
Main objective: Part A: To evaluate the safety and tolerability of AL102 in subjects withprogressing desmoid tumorsPart B: To evaluate effects of AL102 on disease progression in subjectswith progressing desmoid tumorsOLE: To evaluate the safety and…